Heron's pain is Pacira's gain.
These two growth stocks are poised for enormous gains.
They could be big winners for patient investors.
Exelixis and Supernus Pharmaceuticals are deeply undervalued healthcare plays.
HEXO's stock has been heating up, but there's more upside to come. Here's why.
Axsome Therapeutics and PhaseBio Pharmaceuticals are soaring this year, but the best could be yet to come for each of these red-hot biotech stocks.
Atara Biotherapeutics and Crispr Therapeutics stand out as strong takeover candidates. Here's why.
Amarin's stock is stuck in a rut, but this quiet period might turn out to be a great buying opportunity.
These three cancer stocks have tremendous upside potential.
A new gene therapy could be a functional cure for "bubble boy" disease.
The stock price of this clinical-stage biotech has nearly doubled so far in 2019.
GW Pharmaceuticals, Illumina, and Intercept Pharmaceuticals could all be great buys this month.
The FDA refused to accept the biotech's experimental epilepsy medication for review.
Galapagos' experimental rheumatoid arthritis drug hit the mark in two late-stage studies last month.
Viking's shares received a boost from a pair of catalysts last month.
These three biotech stocks are worth buying this month.
Catalyst's new orphan drug is off to a strong start.
The biotech's misstep in Alzheimer's disease proved costly for shareholders last month.
Which of these two pioneering cannabis plays is the better buy right now?
These two biotechs have been stellar growth vehicles for investors, but only one stock is worth buying right now.